All stock lists
Jones Lang Lasalle Inc (New York Stock Exchange:JLL)
US · Delayed Price · Currency is USD
Also listed: 0JPB.LReal Estate · Real Estate - Services
299.87-0.43 (-0.14%)
Market cap
$13.8B
Health Score
Analyst consensus
Listed since
Jul 17, 1997
Website
Insider Score
––Not scored
JLL Insider Score
Insiders filed in the last 90 days, but none of those trades qualified for scoring — round-trip buys and filings whose price is far off the market are excluded.
JLL analyst forecast
JLL analyst consensus
Moderate Buy2 ratings
Buy 1 Hold 1 Sell 0
Based on each firm’s most recent rating in the last 3 months — one vote per firm, so a desk that reiterates weekly does not count three times.
JLL 12-month price target
No published price targets in the last 12 months.
Best analysts covering JLL
- Keefe, Bruyette & Woods100%success rate · 4 calls
- UBS83%success rate · 6 calls
- Goldman Sachs50%success rate · 4 calls
Measured by us from each firm’s own rating dates and this stock’s split- and dividend-adjusted closes. How we calculate this.
JLL analyst ratings
| Firm | Price target | Action | ||||
|---|---|---|---|---|---|---|
| — | Keefe, Bruyette & Woods | Outperform | — | — | Reiterated | 2026-10-09 |
| — | Barclays | Equal Weight | — | — | Reiterated | 2026-08-17 |
| — | Keefe, Bruyette & Woods | Outperform | — | — | Reiterated | 2026-08-03 |
| — | Barclays | Equal Weight | — | — | Reiterated | 2026-07-28 |
| — | Barclays | Equal Weight | — | — | Reiterated | 2026-05-13 |
| — | UBS | Buy | — | — | Reiterated | 2026-04-22 |
| — | Barclays | Equal Weight | — | — | Reiterated | 2026-04-14 |
| — | Barclays | Equal Weight | — | — | Reiterated | 2026-03-13 |
| — | Keefe, Bruyette & Woods | Outperform | — | — | Reiterated | 2026-02-24 |
| — | UBS | Buy | — | — | Reiterated | 2026-02-23 |
| — | UBS | Buy | — | — | Reiterated | 2026-01-28 |
| — | Keefe, Bruyette & Woods | Outperform | — | — | Reiterated | 2026-01-08 |
| — | Goldman Sachs | Buy | — | — | Reiterated | 2025-11-26 |
| — | UBS | Buy | — | — | Reiterated | 2025-10-10 |
| — | Keefe, Bruyette & Woods | Outperform | — | — | Reiterated | 2025-10-09 |
| — | JP Morgan | Overweight | — | — | Reiterated | 2025-08-26 |
| — | Goldman Sachs | Buy | — | — | Reiterated | 2025-08-13 |
| — | Keefe, Bruyette & Woods | Outperform | — | — | Reiterated | 2025-07-24 |
| — | UBS | Buy | — | — | Reiterated | 2025-07-02 |
| — | Citigroup | Neutral | — | — | Reiterated | 2025-05-28 |
| — | Keefe, Bruyette & Woods | Outperform | — | — | Reiterated | 2025-04-17 |
| — | UBS | Buy | — | — | Reiterated | 2025-04-11 |
| — | JP Morgan | Overweight | — | — | Reiterated | 2025-04-10 |
| — | Raymond James | Strong Buy | — | — | Reiterated | 2025-01-24 |
| — | JP Morgan | Overweight | — | — | Reiterated | 2024-12-16 |
| — | Keefe, Bruyette & Woods | Outperform | — | — | Upgraded | 2024-12-10 |
| — | Wolfe Research | Outperform | — | — | Upgraded | 2024-11-25 |
| — | Keefe, Bruyette & Woods | Market Perform | — | — | Reiterated | 2024-11-12 |
| — | Keefe, Bruyette & Woods | Market Perform | — | — | Reiterated | 2024-08-08 |
| — | Keefe, Bruyette & Woods | Market Perform | — | — | Reiterated | 2024-07-25 |
| — | Raymond James | Strong Buy | — | — | Reiterated | 2024-07-25 |
| — | UBS | Buy | — | — | Reiterated | 2024-07-03 |
| — | JP Morgan | Overweight | — | — | Reiterated | 2024-06-21 |
| — | Keefe, Bruyette & Woods | Market Perform | — | — | Reiterated | 2024-05-08 |
| — | Wolfe Research | Peer Perform | — | — | Downgraded | 2024-04-09 |
| — | Wolfe Research | Peer Perform | — | — | Downgraded | 2024-04-08 |
| — | Raymond James | Strong Buy | — | — | Upgraded | 2024-04-03 |
| — | Raymond James | Outperform | — | — | Reiterated | 2024-01-25 |
| — | UBS | Buy | — | — | Reiterated | 2023-11-22 |
| — | Raymond James | Outperform | — | — | Reiterated | 2023-10-04 |
| — | Citigroup | Neutral | — | — | Reiterated | 2023-09-18 |
| — | Raymond James | Outperform | — | — | Reiterated | 2023-07-24 |
| — | Keefe, Bruyette & Woods | Market Perform | — | — | Reiterated | 2023-04-24 |
| — | Goldman Sachs | Sell | — | — | Reiterated | 2023-04-11 |
| — | Goldman Sachs | Sell | — | — | Reiterated | 2023-04-10 |
| — | Citigroup | Neutral | — | — | Reiterated | 2023-03-28 |
| — | Wolfe Research | Outperform | — | — | Upgraded | 2023-03-16 |
| — | JP Morgan | Overweight | — | — | Reiterated | 2023-03-03 |
| — | Wolfe Research | Peer Perform | — | — | Downgraded | 2023-02-01 |
| — | Raymond James | Outperform | — | — | Reiterated | 2023-01-20 |
| — | Raymond James | Outperform | — | — | Reiterated | 2022-11-03 |
| — | Raymond James | Outperform | — | — | Reiterated | 2022-10-20 |
| — | Goldman Sachs | Sell | — | — | Reiterated | 2022-10-19 |
| — | UBS | Buy | — | — | Reiterated | 2022-09-21 |
| — | Raymond James | Outperform | — | — | Reiterated | 2022-08-04 |
| — | Raymond James | Outperform | — | — | Reiterated | 2022-07-22 |
| — | Raymond James | Outperform | — | — | Reiterated | 2022-04-26 |
| — | Wolfe Research | Outperform | — | — | Reiterated | 2022-03-10 |
| — | Raymond James | Outperform | — | — | Reiterated | 2022-01-21 |
| — | Raymond James | Outperform | — | — | Reiterated | 2021-11-04 |
JLL earnings vs. estimates
| Quarter | EPS est. | EPS actual | Revenue est. | Revenue actual |
|---|---|---|---|---|
| 2026-02-18 | 7.25 | 8.71 | $7.44B | $7.61B |
| 2026-04-30 | 3.01 | 3.43 | $6.00B | $6.39B |
| 2026-07-30 | 4.56 | 5.26 | $6.88B | $6.93B |
| 2026-10-28 | 6.15 | 0.00 | $7.24B | $0 |
Disclaimer — Informational only — not investment advice. Insider transaction data is sourced from SEC Form 4 filings; market data from public feeds and may be delayed. The Insider Score is a proprietary score for research purposes and does not predict future performance. Always do your own research.